3D structure generation, virtual screening and docking of human Ras-associated binding (Rab3A) protein involved in

Sharad S Lodhi1, Rohit Farmer, Atul Kumar Singh

  • 1School of Studies in Biochemistry, Jiwaji University, Gwalior, 474011, India.

Insights

Researchers modeled the Rab3A protein structure and screened compounds to find potential inhibitors. A top molecule, ZINC13152284, showed promising binding affinity for Rab3A, suggesting it could be a starting point for developing new drugs.

Area of Science:

  • Computational biology and structural bioinformatics
  • Neuroscience and cancer research

Background:

  • Rab3A protein is predominantly expressed in brain and synaptic vesicles.
  • It plays a role in neurotransmitter release, and its upregulation is linked to certain cancers.
  • The precise function of Rab3A remains under investigation.

Purpose of the Study:

  • To model the 3D structure of Rab3A protein.
  • To identify potential high-affinity inhibitors of Rab3A using molecular docking.
  • To analyze protein-ligand interactions for drug development.

Main Methods:

  • Protein structure modeling using MODELLER 9v8.
  • Molecular docking of GTP and small molecules (NCI diversity set II) using GOLD and GLIDE.
  • Analysis of binding affinity and interactions using X-Score and Ligplot.

Main Results:

  • The Rab3A-GTP complex showed a GOLD fitness value of 77.73, with identified hydrogen bonding and hydrophobic interactions.
  • Screening identified five compounds with potential inhibitory activity against Rab3A.
  • The top-ranked compound, ZINC13152284, exhibited strong binding affinity (Glide score: -6.65 kcal/mol, X-Score: -3.02 kcal/mol) with favorable interactions.

Conclusions:

  • Computational modeling and docking successfully identified potential inhibitors for Rab3A.
  • ZINC13152284 represents a promising lead compound for developing novel Rab3A inhibitors.
  • Further studies are warranted to explore the therapeutic potential of these identified compounds.

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
5.7K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.4K
Rab Proteins01:14

Rab Proteins

Rab proteins constitute the largest family of monomeric GTPases, of which 70 members are present in humans. Rab proteins and their effectors regulate consecutive stages of vesicle transport such as vesicle transport, docking, and fusion to the correct recipient membrane.
Rab proteins switch between a cytosolic, GDP-bound inactive state and a membrane-anchored, GTP-bound active state. By themselves, Rabs show slow rates of GDP/GTP exchange and GTP hydrolysis. Thus, Rab proteins are considered...
4.0K
The Ras Gene02:38

The Ras Gene

2.3K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.9K